Hailey Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hailey Hu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Karan Mediratta
Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
1 shared publication - Lisheng Wang
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canada
1 shared publication - Marena D. Diab
Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
1 shared publication - Peter Han
Department of Biochemistry, Immunology and Microbiology, University of Ottawa, Ottawa, ON K1H 8M5, Canada
1 shared publication
Latest Publications
- Open Access
- 15 September 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (18) , 1418
Emerging Strategies for Cargo Loading and Engineering of Extracellular Vesicles for Breast Cancer Treatment
Breast cancer has now surpassed lung cancer as the leading cause of cancer-related deaths among women worldwide. Given the urgent need for more effective treatment, extracellular vesicles (EVs) have gained attention as versatile and promising drug delivery systems. Derived from a variety of cell types, EVs can be loaded with therapeutic cargo or engineered to present specific surface ligands and receptors. These EV modifications enable them to overcome many limitations associated with conventional therapies. In this review, we highlight current methodologies for loading small molecule drugs, RNA-based therapeutics, and proteins into EVs through both pre-isolation (endogenous) and post-isolation (exogenous) methods. We further discuss recent advances in EV surface engineering strategies aimed at improving tumor-specific targeting and immunotherapeutic efficacy in breast cancer.
- 15 September 2025
- Published by MDPI AG in Nanomaterials
- Vol. 15 (18) , 1418
Open AccessEmerging Strategies for Cargo Loading and Engineering of Extracellular Vesicles for Breast Cancer Treatment
Breast cancer has now surpassed lung cancer as the leading cause of cancer-related deaths among women worldwide. Given the urgent need for more effective treatment, extracellular vesicles (EVs) have gained attention as versatile and promising drug delivery systems. Derived from a variety of cell types, EVs can be loaded with therapeutic cargo or engineered to present specific surface ligands and receptors. These EV modifications enable them to overcome many limitations associated with conventional therapies. In this review, we highlight current methodologies for loading small molecule drugs, RNA-based therapeutics, and proteins into EVs through both pre-isolation (endogenous) and post-isolation (exogenous) methods. We further discuss recent advances in EV surface engineering strategies aimed at improving tumor-specific targeting and immunotherapeutic efficacy in breast cancer.